This page covers biotechnology and pharmaceutical companies developing treatments that target the intersection of metabolic dysfunction and Parkinson's disease (PD). Research has established strong epidemiological and mechanistic links between metabolic disorders (type 2 diabetes, obesity, metabolic syndrome) and Parkinson's disease risk and progression. [1]
The metabolic-PD intersection represents a promising therapeutic approach because:
GLP-1 receptor agonists have emerged as the leading therapeutic class for the PD-metabolic intersection. GLP-1 receptors are expressed in the brain, and activation provides neuroprotection through multiple mechanisms:
Metabolic dysfunction in PD is closely tied to mitochondrial impairment:
Insulin resistance in the brain is a emerging target:
Ticker: NASDAQ: NVO
Headquarters: Copenhagen, Denmark
Novo Nordisk is the leading developer of GLP-1 receptor agonists for neurodegenerative diseases. Their PD programs include:
| Drug | Mechanism | Phase | Status |
|---|---|---|---|
| Semaglutide | GLP-1 RA | Phase 2 | Completed |
| Semaglutide | GLP-1 RA | Phase 3 (AD) | Recruiting |
The company has leveraged its expertise in metabolic diseases to pursue neurodegenerative applications, with semaglutide (Ozempic/Wegovy) being evaluated in PD clinical trials. [2]
Related pages:
Headquarters: Baltimore, Maryland, USA
Neuraly is a clinical-stage biotechnology company focused on developing GLP-1 receptor agonists for neurodegenerative diseases. Their lead candidate NLY01 (Pegcreatecan) is a long-acting GLP-1R agonist designed to penetrate the blood-brain barrier.
| Drug | Mechanism | Phase | Status |
|---|---|---|---|
| NLY01 | GLP-1R agonist | Phase 2 | Completed |
NLY01 works through multiple neuroprotective pathways:
The Phase 2 trial in early Parkinson's disease completed in 2024. The trial demonstrated safety but did not meet its primary efficacy endpoint, informing ongoing research in this space.
Related pages:
Ticker: NYSE: LLY
Headquarters: Indianapolis, Indiana, USA
Eli Lilly has an active neuroscience program including metabolic-based approaches for neurodegenerative diseases. Their GLP-1 portfolio and broader metabolic expertise positions them as a key player in this intersection.
Lilly's approach to neurodegenerative diseases includes:
Related pages:
Headquarters: Cambridge, Massachusetts, USA
Cytochrome Therapeutics is developing CT-101, a first-in-class small molecule that restores mitochondrial Complex I function. The company targets the fundamental bioenergetic defect that underlies dopaminergic neuron degeneration in PD.
Rationale:
Related pages:
Ticker: NASDAQ: CLNN
Headquarters: Salt Lake City, Utah, USA
Clene develops CNM-Au8, a gold nanocatalytic therapeutic that addresses mitochondrial dysfunction in Parkinson's disease. The REPAIR-PD trial (NCT03815916) evaluated this approach.
Mechanism:
Related pages:
Ticker: NASDAQ: IKT
Headquarters: Boston, Massachusetts, USA
Inhibikase develops IkT-148009, a c-Abl tyrosine kinase inhibitor for Parkinson's disease. While not directly metabolic, c-Abl activation is induced by cellular stress including metabolic dysfunction, linking to the broader metabolic-PD intersection.
Related pages:
Several additional companies have programs that intersect with metabolic dysfunction in PD:
| Company | Approach | Status |
|---|---|---|
| Mapi Pharma | GA-GLP-1 (enhanced brain penetration) | Preclinical |
| Kallyope | Gut-brain axis modulators | Discovery |
| Axial Therapeutics | Microbiome-based approaches | Clinical |
| Trial ID | Drug | Company | Phase | Status |
|---|---|---|---|---|
| NCT05024240 | NLY01 | Neuraly | Phase 2 | Completed |
| NCT04875359 | Semaglutide | Novo Nordisk | Phase 2 | Completed |
The field has learned from both positive and negative trial results, informing next-generation approaches:
Key shared pathways between metabolic disorders and PD: [3]